Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × INDUSTRY × regorafenib × Clear all

Phase

Phase 1 17 Phase 3 13 Phase 2 13 Phase 1/2 8 Phase 4 2 Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 3 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 Gastrointestinal 1

Conditions

Gastrointestinal Stromal Tumors 1

Interventions

pembrolizumab 23 Cisplatin 23 Gemcitabine 22 Carboplatin 21 Paclitaxel 19 Docetaxel 13 Pemetrexed 12 Drug Therapy 12 Oxaliplatin 11 Capecitabine 11 Bevacizumab 10 Nivolumab 9 Fluorouracil 9 130-nm albumin-bound paclitaxel 7 anlotinib 6 Trastuzumab 6 Temozolomide 5 atezolizumab 4 Rituximab 4 Leucovorin 4 Lenalidomide 4 Ipilimumab 4 Injections 4 Folfox protocol 4 venetoclax 3 pertuzumab 3 osimertinib 3 daratumumab 3 camrelizumab 3 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07379047 2026-01-30

GISTAR-1

Ningbo Newbay Technology Development Co., Ltd

Phase 2/3 Not yet recruiting

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡